Low-density neutrophil heterogeneity and spleen tyrosine kinase as therapeutic targets in sepsis
Heather L. Teague, Lauren Knabe, Raquel S. Da Cruz, Xianglan Yao, Kiana C. Allen, Trenton Williams, Cumhur Y. Demirkale, Merte Woldehanna, Ernest Evans, Amir Hobson, Jared D. Wilkinson, Steven D. Nathan, Christopher S. King, Jeffrey R. Strich
Heather L. Teague, Lauren Knabe, Raquel S. Da Cruz, Xianglan Yao, Kiana C. Allen, Trenton Williams, Cumhur Y. Demirkale, Merte Woldehanna, Ernest Evans, Amir Hobson, Jared D. Wilkinson, Steven D. Nathan, Christopher S. King, Jeffrey R. Strich
View: Text | PDF
Research Article Immunology Inflammation

Low-density neutrophil heterogeneity and spleen tyrosine kinase as therapeutic targets in sepsis

Abstract

Sepsis is a leading cause of death for which host-directed therapies are urgently needed. We performed high-dimensional flow cytometry, measurement of soluble biomarkers, and lipopolysaccharide (LPS) stimulation of neutrophils to characterize neutrophil heterogeneity and function in patients with sepsis. We observed that in patients with sepsis, low-density neutrophils (LDNs) are elevated and phenotypically diverse populations of innate immune cells with varying degrees of maturity and myeloperoxidase expression. Spleen tyrosine kinase (SYK) expression was found to be higher in whole blood neutrophils and LDNs of patients with sepsis compared with healthy donors. Importantly, SYK+ LDNs associated with increased levels of intracellular myeloperoxidase (MPO) and soluble biomarkers. Furthermore, SYK+ LDNs correlated with clinical outcomes of sepsis disease severity, including sequential organ failure assessment score, mechanical ventilation, and vasopressors. Functionally, the SYK inhibitor R406 suppressed changes in neutrophil features of activation from normal-density neutrophils and LDNs, including the SYK+ and SYK– neutrophil subsets, and MPO release from LDNs following LPS stimulation of sepsis neutrophils. Combined, these results establish LDNs as a heterogenous population of neutrophils that express high levels of SYK and support SYK inhibition as a potentially novel therapeutic target aimed at suppressing overactive neutrophils in sepsis.

Authors

Heather L. Teague, Lauren Knabe, Raquel S. Da Cruz, Xianglan Yao, Kiana C. Allen, Trenton Williams, Cumhur Y. Demirkale, Merte Woldehanna, Ernest Evans, Amir Hobson, Jared D. Wilkinson, Steven D. Nathan, Christopher S. King, Jeffrey R. Strich

×

Figure 6

Characterization of SYK+ and SYK– neutrophil subsets from patients with sepsis.

Options: View larger image (or click on image) Download as PowerPoint
Characterization of SYK+ and SYK– neutrophil subsets from patients with ...
(A) Dumbbell plot comparing the percentage of expression of each extracellular and intracellular feature across SYK– WBNs (gray) and SYK+ WBNs (color), (B) SYK– LDNs (gray) and SYK+ LDNs (color), and (C) SYK+ WBNs (gray) and SYK+ LDNs (color). The size of the circle represents the magnitude of the percentage of each extracellular and intracellular feature, and the distance between the circles represents the percentage difference between each feature for the neutrophil subsets being compared. (D) Heatmap representing the relative expression of each extracellular and intracellular feature between healthy donor SYK+ WBNs, healthy donor SYK– WBNs, sepsis SYK+ WBNs, sepsis SYK– WBNs, sepsis SYK+ LDNs, and sepsis SYK– LDNs. Data are represented as means ± SEM. Significance was determined using a paired t test or a Wilcoxon test and set at P < 0.05*, P < 0.01**, P < 0.001***, P < 0.0001****. SYK, spleen tyrosine kinase; HD, healthy donor; Sep, sepsis; WBNs, whole blood neutrophils; LDNs, low-density neutrophils; SEM, standard error of the mean.